Fact-checked by Grok 2 weeks ago

Fel d 1

Fel d 1 is the major secreted by domestic (Felis catus), a small belonging to the secretoglobin superfamily that elicits IgE-mediated reactions in up to 95% of individuals with cat allergy. Structurally, it forms a compact, all-helical tetramer of approximately 35–38 , consisting of two disulfide-linked heterodimers each made from chain 1 (70 , ~8 ) and chain 2 (85–92 , ~10 ), with an internal and two calcium-binding sites. Produced primarily in sebaceous glands and also in salivary and anal glands, Fel d 1 is transferred to fur and during grooming, rendering it highly airborne and persistent in environments, with concentrations detectable in up to 99.9% of homes. The biological function of Fel d 1 remains unclear, though it may serve as a carrier for lipids, steroids, or pheromones, or contribute to skin protection and immune modulation akin to other secretoglobins like uteroglobin. Encoded by two linked genes on chromosome A1 (CH1 and CH2), it exhibits isoforms due to variations in chain 2 length, with higher production in intact male cats compared to females or neutered males. As the dominant cat allergen, Fel d 1 accounts for 60–90% of the total IgE reactivity to cat dander and is recognized by mannose receptors on antigen-presenting cells, promoting a Th2-biased immune response that correlates with asthma severity in sensitized individuals. Its thermostability and adhesion to small particles (<5 μm) facilitate widespread dispersal, contributing to sensitization rates of 10–30% in the general population and 20–40% among atopics. Ongoing research focuses on mitigating Fel d 1's allergenicity, including recombinant forms for diagnostics and , vaccines, and via CRISPR-Cas9 to knock out chain 2 expression, yielding cats with over 98% reduced salivary Fel d 1 levels (as demonstrated in 2024 studies, with 2025 research further confirming feasibility through CH2 knockouts in cells). These advances highlight Fel d 1's central role in allergy management, affecting an estimated 10–20% of the global population with pet allergies.

Discovery and Characterization

Initial Identification

The identification of Fel d 1 as the primary emerged in the early 1970s through investigations into and pelt extracts using skin prick tests to assess allergic responses in sensitized individuals. Early work focused on extracting and characterizing components from cat pelts, revealing a dominant allergenic fraction responsible for most reactions in cat-allergic patients. Researchers such as Francis C. Lowell and Jack L. Ohman Jr., in collaboration with Kurt J. Bloch, pioneered these efforts, with a 1973 study detailing the extraction process and initial biochemical properties of the from sources. By the mid-1970s, the advent of radioallergosorbent tests (RAST) enabled more precise detection of IgE antibodies specific to cat allergens, confirming the major component's role in hypersensitivity. Ohman and Lowell's 1977 study quantified IgE binding in an allergic population, demonstrating that this dominant allergen elicited responses in the majority of cat-sensitive individuals, laying the groundwork for its recognition as the principal mediator of cat allergy. These findings highlighted the allergen's prevalence, with subsequent early analyses showing it accounted for 60-90% of cat-specific IgE responses among affected patients. Isolation and purification advanced in the 1970s using techniques such as gel filtration on Sephadex columns and ion-exchange on DEAE-cellulose, which separated the major from crude extracts for detailed study. These methods allowed for partial purification, enabling antigenic and allergenic characterization that solidified its status. In 1988, the International Union of Immunological Societies (IUIS) formally designated it as Fel d 1, standardizing nomenclature for this secretoglobin-like protein and facilitating global research consistency.

Biochemical Classification

Fel d 1 belongs to the secretoglobin superfamily, a group of small, secreted proteins also known as uteroglobin-like proteins, which are characterized by their compact structures and roles in modulating inflammatory responses. As a tetrameric glycoprotein, Fel d 1 exhibits a molecular weight of approximately 35-38 kDa, consisting of two disulfide-linked heterodimers each formed by chain 1 (α-chain) and chain 2 (β-chain). This classification underscores its evolutionary relation to other secretoglobins, such as rabbit uteroglobin, which shares structural similarities despite functional differences. The protein is encoded by two distinct genes: CH1, which produces the α-chain, and , which produces the β-chain. These genes are located in close proximity on feline chromosome E2, within a region spanning less than 10,000 base pairs, facilitating coordinated expression. The CH1 gene comprises three exons separated by two introns, while the gene structure supports the production of two isoforms—a long form of 92 preferentially expressed in salivary glands and a short form of 90 —through alternative processing. Post-translational modifications are essential for Fel d 1's stability and function, including N-linked primarily at residue 33 (Asn33) in the β-chain (chain 2), which contributes to structural heterogeneity via variable attachments. Additionally, three interchain bonds covalently link the chains within each heterodimer, forming the mature tetrameric structure and enhancing resistance to denaturation. Fel d 1 is an acidic protein with an (pI) of approximately 5.0, which promotes its solubility in salivary and sebaceous secretions where it is predominantly found. This low pI reflects its high content of negatively charged residues, aiding in its dispersal and persistence in the .

Molecular Structure

Protein Composition

Fel d 1 is a heterodimeric protein composed of two distinct polypeptide chains, designated chain 1 (also known as α or CH1) and chain 2 (β or ), which are encoded by separate genes and covalently linked by three interchain bonds. Each chain is synthesized as a precursor with an N-terminal that is cleaved during maturation, yielding the functional mature proteins. In its native state, the heterodimer often assembles into dimers or tetramers through non-covalent interactions, resulting in a complex with an overall molecular weight of approximately 35-38 kDa. Chain 1 comprises 70 and has a molecular weight of about 8 kDa, featuring conserved cysteine residues that contribute to structural integrity. Chain 2 is slightly larger, consisting of 92 (though natural forms may include truncated variants of 85 or 90 residues) with a molecular weight of approximately 10 kDa, and it shares structural motifs with chain 1, including positions for linkage. The bridges critical for heterodimer stability are formed between Cys3 of chain 1 and Cys73 of chain 2, Cys44(1) and Cys48(2), and Cys70(1) and Cys7(2). Sequence analysis of Fel d 1 from domestic cats reveals polymorphisms leading to isoform variability, with over 30 unique substitutions documented, including more than 20 distinct variants. Despite this , the core is highly conserved across individuals, exhibiting 92-99% , which underscores the protein's functional consistency as a major .

Three-Dimensional Conformation

Fel d 1 exhibits a compact globular fold typical of the secretoglobin family, forming a tetramer composed of two non-covalently associated heterodimers, with each heterodimer consisting of chain 1 (70 ) and chain 2 (85–92 ) covalently linked by three interchain bonds. Each chain adopts an all-α-helical structure with four α-helices that pack together to create a hydrophobic core, providing essential for the protein's function as an . This helical bundle arrangement results in a compact monomer-like unit per heterodimer, with the overall tetrameric assembly reaching a molecular weight of approximately 35–38 kDa. The three-dimensional structure of Fel d 1 was elucidated through , with a seminal study reporting the atomic model of a recombinant heterodimer mimic (chains 2 and 1 fused without a linker) at 1.85 resolution using multi-wavelength anomalous on selenomethionine-substituted protein. This high-resolution structure reveals eight α-helices in total (four per chain), an internal asymmetric cavity potentially capable of binding amphipathic ligands such as steroids or fatty acids, and surface-exposed regions critical for immunological interactions. Subsequent refinements, including a 1.64 structure of the natural heterodimer (PDB ID: 1ZKR), confirm the helical packing and connectivity, with cysteines at positions 3, 44, and 70 in chain 1 forming bonds to Cys73, Cys48, and Cys7 in chain 2, respectively. The between the two heterodimers in the tetrameric form is primarily stabilized by hydrophobic interactions involving non-polar residues from the helical surfaces, enhancing the protein's environmental persistence and resistance to denaturation. This arrangement buries significant surface area, approximately 1,200 Ų per , which contributes to the overall and may modulate of functional . The tetrameric also features two calcium-binding : one external symmetrically positioned on each side of the tetramer and another within the dimerization , contributing to . Epitope mapping has localized key IgE-binding sites to exposed loops on the protein surface, with major conformational epitopes identified in residues 25–38 (VAQYKALPVVLENA) and 46–59 on chain 1, and residues 15–28 on chain 2. The positions these epitopes prominently on the exterior, away from the hydrophobic core and dimer interface, facilitating recognition while the helical fold and disulfides maintain structural integrity during immune encounters. These surface features underscore the role of the three-dimensional conformation in Fel d 1's allergenicity, as disruptions to the fold can alter exposure and IgE affinity.

Production and Variation in Cats

Sites of Synthesis

Fel d 1 is primarily synthesized in the submandibular and sublingual salivary glands, sebaceous glands of the skin, and anal sacs of domestic cats, with these sites accounting for the majority of the allergen's production. Sebaceous glands represent the predominant source, contributing to direct secretion through skin oils, while salivary production occurs mainly in the sublingual glands. Anal sacs also serve as a significant reservoir, with Fel d 1 levels detected at high concentrations in their secretions. Minor synthesis takes place in the lacrimal glands, where Fel d 1 concentrations in lacrimal fluid are comparable to those in , ranging from 6.8 to 14 units per milliliter. Following synthesis, Fel d 1 is secreted into , facilitating its transfer to the fur and during grooming behaviors, which spreads the across the cat's coat. Sebaceous gland-derived Fel d 1 is released directly onto surface via sebum, embedding in the and shafts. At the cellular level, expression occurs predominantly in glandular epithelial cells, including sebaceous cells within glands and squamous epithelial cells in associated tissues.

Factors Influencing Levels

The production of Fel d 1 in cats exhibits notable , with intact male cats generally producing higher levels than females due to hormonal regulation by testosterone. Studies have shown that male cats secrete significantly more Fel d 1 than female cats, primarily originating from sources. intact males leads to a substantial reduction in Fel d 1 production, with levels decreasing to approximately one-third to one-fifth of pre-neutering amounts, corresponding to a 67-80% drop in output. This hormonal influence underscores the role of androgens in modulating expression, though specific promoter elements remain under investigation. Breed-specific differences also contribute to variability in Fel d 1 levels, with certain breeds demonstrating inherently lower production due to genetic factors. For instance, Siberian cats often exhibit reduced Fel d 1 secretion compared to other breeds, with about 50% of individuals producing lower levels and roughly 15% showing exceptionally low amounts, attributed to polymorphisms in the CH1 and genes that encode the . Similarly, cats are noted for lower Fel d 1 output linked to their genetic makeup, making them relatively . These variations arise from sequence differences in the Fel d 1 genes, with up to 58% variability in the CH2 chain across populations, enabling for reduced allergenicity. Age and seasonal factors further influence Fel d 1 levels over time. Younger cats, particularly young adults, tend to produce higher salivary Fel d 1 concentrations than older individuals, with levels declining as cats age. Seasonally, Fel d 1 peaks during winter and , coinciding with periods when hormonal fluctuations may enhance production, though levels remain relatively stable year-round in neutered cats. Individual cats also display consistent "low-shedder" profiles, driven by genetic , as evidenced by high inter-cat variability and familial patterns in allergen output, with studies estimating a moderate genetic component to production differences.

Allergenicity in Humans

Immunological Response

Fel d 1 elicits an IgE-mediated reaction in sensitized individuals, where the binds to IgE antibodies already attached to the high-affinity FcεRI receptors on the surface of mast cells and . This binding cross-links adjacent IgE-FcεRI complexes, triggering intracellular signaling cascades that lead to rapid of these cells, releasing preformed mediators such as , as well as newly synthesized cytokines like IL-4, IL-5, and IL-13. The histamine release contributes to immediate symptoms, while cytokines amplify the inflammatory response by promoting recruitment and further IgE production. The process begins with exposure to Fel d 1 through or contact, where the is taken up by antigen-presenting cells (APCs), such as dendritic cells, via receptors. Within APCs, Fel d 1 is processed into peptides and presented on molecules to naïve T cells, preferentially driving differentiation into Th2 cells in genetically susceptible individuals. Th2 cells then secrete cytokines including IL-4 and IL-13, which stimulate B cells to undergo class-switch recombination and produce Fel d 1-specific IgE antibodies that circulate and bind to FcεRI on effector cells, priming them for future encounters with the . Cross-reactivity of Fel d 1 with other allergens is generally limited among secretoglobins but has been observed with certain components in dog dander, such as a 20 kDa protein that shares IgE-reactive epitopes, potentially due to conformational similarities. This may explain dual in some patients allergic to both and , although it does not extend broadly to the major dog Can f 1. The dose-response relationship for Fel d 1 involves airborne concentrations below 100 ng/m³ sufficient to provoke reactions in sensitized individuals, with higher levels correlating to more severe responses. The affinity of IgE for Fel d 1 is in the sub-nanomolar range (Kd ≈ 10^{-9} M), enabling efficient cross-linking even at low doses.

Clinical Impact

Fel d 1 is the primary responsible for , affecting 10-20% of the global population in regions with high ownership rates. Among individuals allergic to , 80-95% exhibit sensitization specifically to Fel d 1, as measured by detectable IgE antibodies. This high sensitization rate underscores Fel d 1's dominant role in eliciting allergic responses to . The most common clinical manifestations of Fel d 1 sensitization include rhinoconjunctivitis, characterized by , sneezing, and itchy, watery eyes, as well as asthma exacerbations such as wheezing, , and cough. may also occur, presenting as itchy, inflamed skin or upon exposure. Severe reactions like are rare in cat allergy. Diagnosis of Fel d 1 allergy relies on skin prick tests using Fel d 1 extracts, where a wheal diameter greater than 3 mm indicates positivity, confirming sensitization in symptomatic patients. Serum-specific IgE testing via ImmunoCAP assay is also standard, with levels above 0.35 kU/L denoting clinically relevant sensitization to Fel d 1. Early-life exposure to Fel d 1 has a complex relationship with sensitization risk; while some cohort studies show higher rates among infants in cat-owning households, recent analyses suggest no increased risk or even protective effects against asthma development. Sensitization to Fel d 1 is associated with elevated asthma development, with an odds ratio of 2.6 (95% CI 1.27–5.34) in a longitudinal cohort study of children. Recent studies highlight a dose-response where high early exposure may promote tolerance via modified Th2 responses and IgG4 production.

Distribution and Homologs

Environmental Spread

Fel d 1, the primary cat allergen, disperses into human environments primarily through , attaching to particles ranging from less than 1 to over 20 μm in diameter. These particles, generated from shed skin and fur coated with salivary secretions, can remain suspended in indoor air for several hours, facilitating and subsequent deposition on surfaces such as furniture and flooring. Approximately 60% of airborne Fel d 1 is carried on such small particles, with 75% exceeding 5 μm and 25% below 2.5 μm, enhancing its ability to penetrate deep into the . The allergen exhibits remarkable persistence in the environment, remaining stable on fabrics and upholstery for months due to its resistance to degradation. This longevity allows Fel d 1 to accumulate in reservoirs like carpets, mattresses, and soft furnishings, where it can be resuspended into the air through human activity. Consequently, it has been detected in the settled dust of 95% of homes without cats (38 out of 40 surveyed), primarily through indirect transfer via owners' clothing, hair, or visitors, underscoring its ubiquity even in pet-free settings. Quantification of Fel d 1 in environmental samples relies on sensitive methods such as for dust swabs, which detect levels as low as 0.1 ng/g, and air samplers that measure concentrations in the range of ng/m³ to μg/m³. These techniques enable assessment of exposure risks in homes and public spaces, with levels in cat-owning households typically ranging from 0.7 to 38 ng/m³. Key factors influencing Fel d 1 dissemination include grooming behaviors, during which salivary secretions containing the are spread onto the fur and subsequently aerosolized, and environmental controls like , which can significantly reduce concentrations through dilution and particle removal. Regular of cats further mitigates spread by temporarily lowering salivary and Fel d 1 by up to 79%.

Presence in Other Species

Fel d 1 exhibits high sequence conservation across the family, with protein sequence identities ranging from 80% to 98% between domestic cats and exotic felids such as lions and tigers. Specifically, chain 1 shows approximately 90.4% identity on average among exotic felids, while chain 2 averages 86.9%, reflecting evolutionary divergence within the family but retaining core structural features. This protein is expressed similarly in the salivary glands of these species, contributing to its secretion via grooming behaviors analogous to those in domestic cats. Homologous sequences to Fel d 1 have been identified in other mammals outside the family, displaying 25-50% sequence similarity to proteins like uteroglobin and subunits of prostatein, both members of the secretoglobin superfamily. However, no functional equivalents of Fel d 1 are expressed in non-felid species such as dogs or humans, limiting its presence to the lineage. Bioinformatics analyses have detected Fel d 1 orthologs in 37 exotic felid spanning eight evolutionary lineages, underscoring its broad distribution within the . Evidence of positive selection on epitopes, particularly in chain 2 (observed in 95% of exotic felids), suggests adaptive that may influence immune recognition while preserving overall function. Fel d 1 from wild felids demonstrates significant with human IgE antibodies specific to domestic Fel d 1, with studies showing high cross-reactivity, including 100% in a small of cat-allergic individuals exposed in zoo environments. This cross-reactivity extends to species like lions, tigers, pumas, and jaguars, posing risks for allergic reactions during encounters with big cats in captivity.

Recent Research and Mitigation

Gene Editing Approaches

Gene editing approaches for Fel d 1 primarily utilize CRISPR-Cas9 to target and disrupt the genes encoding its chains, aiming to produce by reducing or eliminating secretion. In a 2025 study, researchers achieved a 40% efficiency for the in fetal fibroblasts using CRISPR-Cas9 with two sgRNAs, resulting in mutations that eliminated key antigenic sites and reduced allergenicity through frameshifts. This success laid groundwork for subsequent applications, demonstrating the feasibility of editing without significant off-target effects. Building on this, a 2024 study generated the first live CH2 genome-edited cats via CRISPR-Cas9 into zygotes, followed by through . Homozygous edited kittens exhibited normal development and viability, with no observed health abnormalities up to several months post-birth. Fel d 1 levels in their and were drastically reduced, reaching less than 1% of wild-type levels (e.g., 0.15 µg/ml in saliva versus 10.69 µg/ml in controls), confirming substantial suppression. Editing the CH1 chain presents greater challenges due to its higher and fewer polymorphic sites compared to , leading to lower targeting success amid multiple alleles. Biallelic edits in models achieved over 98% reduction in expression, but dual CH1/ targeting remains technically demanding and requires further optimization for complete . Ethical considerations include ensuring , as Fel d 1's biological role in cats is not fully understood, potentially affecting reproduction or immunity if disrupted. Commercially, these advances hold promise for developing hypoallergenic breed lines to meet demand from sufferers, but face regulatory hurdles; in the , the FDA classifies intentionally genome-edited animals as new animal drugs, requiring rigorous safety reviews for , animal, and environmental risks before market approval.

Neutralization Methods

Neutralization methods for Fel d 1 focus on strategies that target the allergen post-production, either by binding it in the cat's system or reducing its environmental presence to limit human exposure. These approaches aim to inactivate or block Fel d 1 without altering the cat's genetic expression of the protein. Key techniques include dietary interventions using antibodies, vaccines administered to cats, allergen-specific immunotherapy for humans, and environmental controls. One prominent antibody-based method involves incorporating chicken-derived IgY antibodies specific to Fel d 1 into , such as the Pro Plan LiveClear formula introduced in 2019. These antibodies bind to Fel d 1 in the cat's digestive tract, facilitating its via feces and thereby reducing the amount of active secreted in and subsequently transferred to during grooming. A clinical study demonstrated that feeding this diet to cats resulted in a 47% reduction in active Fel d 1 levels on their after three weeks, with effects persisting over longer periods of use. This approach is non-invasive and safe for cats, offering a practical way for pet owners to mitigate allergen spread in the household. Vaccine development represents another strategy, where are immunized to produce their own neutralizing antibodies against Fel d 1. The HypoCat , tested in trials during the and , utilized a recombinant Fel d 1 conjugated to a to induce high-titer IgG antibodies in that bind and neutralize the in bodily secretions. Studies involving over 70 showed that led to a reduction of up to 60% in active Fel d 1 levels, correlating with decreased allergic symptoms in exposed humans. Although the HypoCat program was discontinued, its findings have provided foundational insights for subsequent designs targeting feline allergens. For human patients, allergen-specific (AIT) using extracts from cat dander offers a direct approach by gradually desensitizing the to allergens including Fel d 1. Clinical trials of have demonstrated improvements in symptoms for cat-allergic individuals. Recent developments also include therapies, such as the combination REGN1908 and REGN1909, which target Fel d 1 and have shown reductions in early asthmatic responses and symptoms in phase 1/2 trials conducted in 2022. Household interventions provide indirect neutralization by physically removing or trapping Fel d 1 from the air and surfaces. High-efficiency particulate air (HEPA) filters in air purifiers and HVAC systems capture airborne Fel d 1 particles, while regular cat washing and home cleaning further diminish reservoirs. Seminal studies have shown that combining HEPA filtration with cat bathing can reduce airborne Fel d 1 concentrations by approximately 80%, significantly lowering exposure for allergic residents. These non-pharmacological measures are accessible and effective as first-line defenses, particularly in multi-pet homes.

References

  1. [1]
    An update on molecular cat allergens: Fel d 1 and what else ... - NIH
    Apr 10, 2018 · The major allergen responsible for symptoms is Fel d 1, a secretoglobin and not a lipocalin, making the cat a special case among mammals.
  2. [2]
    e94 Fel d 1 | Thermo Fisher Scientific
    Fel d 1 is the most important and major cat allergen as it has been observed in up to 95% of individuals with cat allergy. Sixty to 90% of all IgE reactivity to ...
  3. [3]
    The Crystal Structure of the Major Cat Allergen Fel d 1, a Member of ...
    Fel d 1 elicits IgE responses in 90–95% of patients with cat allergy (3) and accounts for 60–90% of the total allergenic activity in cat dander (4). The ...Missing: scientific review
  4. [4]
    Generation of Fel d 1 chain 2 genome-edited cats by CRISPR-Cas9 ...
    Feb 29, 2024 · In particular, Fel d 1, the major allergen, affects up to 90% of cat-allergic patients and accounts for 60–90% of the overall allergenic ...
  5. [5]
    characterization of allergen extracted from cat pelts - PubMed
    Allergens of mammalian origin: characterization of allergen extracted from cat pelts.Missing: 1969 | Show results with:1969
  6. [6]
    Allergens of mammalian origin. III. Properties of a major ... - PubMed
    Allergens of mammalian origin. III. Properties of a major feline allergen. J Immunol. 1974 Dec;113(6):1668-77. Authors. J L Ohman Jr, F C Lowell, K J Bloch.Missing: 1969 | Show results with:1969
  7. [7]
    IgE Antibody to Cat Allergens in an Allergic Population - PubMed
    IgE Antibody to Cat Allergens in an Allergic Population. ... 1977 Nov;60(5):317-23. doi: 10.1016/0091-6749(77)90112-9. Authors. J L Ohman Jr, F C Lowell.
  8. [8]
    Genetic diversity of the major cat allergen, Fel d 1 | PNAS Nexus
    Nov 26, 2024 · The major cat allergen, Fel d 1, causes IgE antibody-mediated sensitization in nearly 95% of cat allergic patients and accounts for 60–90% of ...Missing: primary | Show results with:primary
  9. [9]
    Cat allergen 1: Biochemical, antigenic, and allergenic properties
    Cat allergen 1, an important agent in human allergic reactions, has been partially purified by affinity chromatography. Heating the purified allergen at 100 ...
  10. [10]
  11. [11]
    The Major Cat Allergen Fel d 1 Binds Steroid and Fatty Acid ...
    Feb 18, 2020 · The major cat allergen Fel d 1 is a tetrameric glycoprotein of the secretoglobin superfamily. Structural aspects and allergenic properties ...
  12. [12]
    Fel d 1 Allergen Details
    Feb 5, 2003 · Allergen name: Fel d 1. Allergen source: Major taxonomic group: Animalia Chordata Order: Carnivora Species: Felis domesticus (F. catus) ...Missing: designation 1988
  13. [13]
    Genetic diversity of the major cat allergen, Fel d 1 - PMC - NIH
    Nov 26, 2024 · The major cat allergen, Fel d 1, causes IgE antibody-mediated sensitization in nearly 95% of cat allergic patients and accounts for 60–90% of ...
  14. [14]
    Targeted Gene Knock-Out of Fel d1 in Fetal Fibroblasts Using ... - NIH
    Mar 24, 2025 · All successfully cloned sequences have three exons and two introns, and no mutation was observed within the exon1, intron1, and exon2 of the CH1 ...
  15. [15]
    Expression and genomic structure of the genes encoding FdI, the ...
    The long form (Ch2L), composed of 92 amino acids (aa), is preferentially expressed in the salivary glands, while the short form (Ch2S), composed of 90 aa, is ...
  16. [16]
    Molecular Characterization of Major Cat Allergen Fel d 1
    Partial deamidation of the asparagine residue was found from peptide F-16 (Table II). Previously deamidation was considered to be a purification artifact ...
  17. [17]
    Major Cat Allergen
    The molecular weight is 38,085.73 Da and its isoelectric point (pl) is 5.00 (6). ... Conformation differs between subunits A and B in Fel d 1 (1+2) in the ...
  18. [18]
    Studies on the biochemical structure of the major cat allergen Felis ...
    The major cat allergen, Fel d I, was purified to homogeneity from cat dander extract by sequential mAb affinity chromatography and HPLC size exclusion.
  19. [19]
    Formation of disulfide bonds and homodimers of the major cat ...
    In this study, a recombinant folded Fel d 1 with molecular and biological properties similar to the natural counterpart was produced.Missing: composition | Show results with:composition<|control11|><|separator|>
  20. [20]
    Evolutionary Biology and Gene Editing of Cat Allergen, Fel d 1
    Mar 28, 2022 · Here, we present a bioinformatics analysis of the major cat allergen, Fel d 1, and demonstrate proof of principle for CRISPR gene editing of the ...
  21. [21]
    (PDF) Genetic diversity of cat allergen, Fel d 1 - ResearchGate
    Aug 6, 2025 · We conducted a comparative analysis of Fel d 1 genes, CH1 and CH2, and investigated structural features of Fel d 1 homologs across the family ...
  22. [22]
  23. [23]
  24. [24]
    1ZKR: Crystal structure of the major cat allergen Fel d 1 (1+2)
    Crystal structure of the major cat allergen Fel d 1 (1+2) ; Find proteins for P30438 (Felis catus).Missing: exons | Show results with:exons
  25. [25]
  26. [26]
    Influence of time and phenotype on salivary Fel d1 in domestic ...
    The main reservoirs of Fel d1 in cats are saliva and hair, and the allergen is produced predominantly in sublingual and sebaceous glands, although anal and ...<|control11|><|separator|>
  27. [27]
    An update on molecular cat allergens: Fel d 1 and what else ...
    Apr 10, 2018 · The major allergen responsible for symptoms is Fel d 1, a secretoglobin and not a lipocalin, making the cat a special case among mammals.Missing: primary | Show results with:primary
  28. [28]
    Fel d I levels in cat anal glands - PubMed
    The close association of Fel d I protein with skin sebaceous glands and anal sacs both with holocrine function and lipids' secretions in one hand, ...Missing: lacrimal preputial
  29. [29]
  30. [30]
    Focus on Cat Allergen (Fel d 1): Immunological and Aerodynamic ...
    Fel d 1 was mainly associated with large carrying particles (>9 µm in diameter) collected on the first stage of the Andersen sampler, the percentage being about ...
  31. [31]
    Detection of an allergen in dog dander that cross‐reacts with the ...
    Dec 20, 2006 · Recombinant Fel d 1, Fel d 1-specific antibodies. Recombinant Fel d 1 ... isoelectric point of 3.4. It represents a target for cross ...
  32. [32]
    Detection of an allergen in dog dander that cross-reacts ... - PubMed
    A 20 kDa Fel d 1 cross-reactive allergen was found in dog dander, which may cause double positivity to cat and dog allergens.
  33. [33]
    A human monoclonal antibody based immunoenzymetric assay to ...
    Jul 15, 2024 · Figures 1A–D depicts high affinity binding to Fel d 1 intrinsic to the variable domains of four human IgE mAbs. All mAbs had sub-nanomolar ...
  34. [34]
    Dog and Cat Allergies: Current State of Diagnostic Approaches and ...
    Feb 1, 2018 · Allergies to dogs and cats affect 10%–20% of the population worldwide and is a growing public health concern as these rates increase.
  35. [35]
    Human allergy to cats: A review for veterinarians on prevalence ...
    The very widespread distribution of Fel d 1 beyond cat-owning homes is regarded as an important source of allergen for bothsensitisation and allergic symptoms.
  36. [36]
    Pet Allergy Symptoms, Diagnosis, Treatment & Management | AAAAI
    Additionally, contact with a pet may trigger skin allergy symptoms including itchy skin or raised, red patches (hives). Pets can also trigger asthma symptoms, ...
  37. [37]
    Allergy to furry animals: New insights, diagnostic approaches, and ...
    Age- and sex-adjusted data from a pan-European study published in 2009 found that 26% and 27% of adults were sensitized to cats and dogs (by using skin prick ...
  38. [38]
    Diagnostics of Allergy to Furry Animals—Possibilities in 2024 - MDPI
    May 30, 2024 · Skin prick tests are the basis of allergy diagnosis, can be performed in an ambulatory setting with the result in 15 min. This inexpensive ...
  39. [39]
    606650: Allergen Profile, Cat, IgE With Component Reflex | Labcorp
    Test Includes Cat IgE; Reflex criteria: If Cat IgE ≥0.35 kU/L, Fel d 1 IgE, Fel d 2 IgE and Fel d 4 IgE will be performed.
  40. [40]
    risk of sensitization and asthma at 4 years in a birth cohort - PubMed
    Conclusion: Early exposure to cat seems to increase the risk of sensitization to cat but not of asthma at 4 years of age. Dog ownership, on the other hand, ...
  41. [41]
    Early-Life Allergen Exposure and Atopy, Asthma, and Wheeze up to ...
    Jul 6, 2006 · Fel d1 showed an association with all these outcomes (third vs. first tertile; odds ratio, 4.43 for positive specific prick test and 2.6 for ...
  42. [42]
    Animal Allergens and Their Presence in the Environment - Frontiers
    Fel d 1 and Can f 1 have been measured in reservoir dust from seats and floors inside public buildings such as hotels, cinemas and pubs (74), hospitals (69), ...Missing: transmission | Show results with:transmission
  43. [43]
    Distribution, aerodynamic characteristics, and removal of the major ...
    Airborne levels of Fel d 1 were detected in all houses with cats, and the levels varied greatly between the homes (range 0.7-38 ng/m3). Low concentrations of ...
  44. [44]
    Minimizing indoor allergen exposure: What works? - PMC - NIH
    Fel d 1 is a “persistent” allergen, and it may take months for the allergen load to be reduced once a cat is removed from the household. One study observed ...<|separator|>
  45. [45]
    Cat antigen in homes with and without cats may induce ... - PubMed
    Fel d 1 was present in the settled dust of 38 of 40 homes without cats (range, 39 to 3750 ng/gm; median, 258 ng/gm), although these levels were only weakly ...Missing: detection percentage transfer clothing<|separator|>
  46. [46]
    Human allergy to cats: A review for veterinarians on prevalence ...
    Oct 8, 2021 · Increasing ventilation will help to reduce airborne Fel d 1 concentrations ... One study demonstrated a mean reduction of 79% in airborne Fel d 1 ...
  47. [47]
    Anti-Fel d1 immunoglobulin Y antibody-containing egg ingredient ...
    Jul 16, 2019 · Fel d1 is the major cat allergen, causing IgE reactions in up to 90% of cat-allergic adults. Fel d1 secreted in saliva is spread to the haircoat ...
  48. [48]
    Evolutionary Biology and Gene Editing of Cat Allergen, Fel d 1
    Mar 28, 2022 · Fel d 1 causes IgE antibody-mediated sensitization in ∼95% of cat allergic patients and accounts for 60–90% of the anti-cat IgE. High ...<|control11|><|separator|>
  49. [49]
    Evidence for a Fel d I-like molecule in the "big cats" (Felidae species)
    In this study, we investigated the cross-reactivity pattern of IgE and IgG4 antibodies to the major feline allergen, Fel d I. We studied the IgE and IgG4 ...Missing: zoo | Show results with:zoo
  50. [50]
    Molecular diagnosis in cat allergy - PMC - PubMed Central
    May 20, 2021 · The benefits of molecular diagnosis in cat allergy include use of the species-specific major allergen Fel d 1, cross-reacting allergen components.Missing: 1988 | Show results with:1988
  51. [51]
    Targeted Gene Knock-Out of Fel d1 in Fetal Fibroblasts Using ...
    There are 2 SNP sites in CH1 exon 2, and the CH2 sequence has a total of 31 SNP sites in other regions. In addition, it was also found that the CH1 sequence in ...Missing: chromosome | Show results with:chromosome
  52. [52]
    Genetic engineering of animals: Ethical issues, including welfare ...
    The genetic engineering of animals has increased significantly in recent years, and the use of this technology brings with it ethical issues, some of which ...Missing: hurdles | Show results with:hurdles
  53. [53]
    Are cats drugs? That's how outdated FDA regulations categorize ...
    Apr 27, 2022 · A controversial company called Lifestyle Pets (formerly Allerca) claimed to have produced hypoallergenic cats using conventional breeding.Missing: hurdles | Show results with:hurdles